This Article OPEN ACCESS ARTICLE Full Text Full Text (PDF) Supplemental Reseach Data Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rada-Iglesias, A. Articles by Wadelius, C. Search for Related Content PubMed PubMed Citation Articles by Rada-Iglesias, A. Articles by Wadelius, C. Social Bookmarking                   What's this?

Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes

¹ Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, SE-751 05 Sweden; ² Linnaeus Centre for Bioinformatics, Uppsala University, Uppsala, SE-751 05 Sweden; ³ Wellcome Trust Sanger Institute, Cambridge, United Kingdom

Butyrate is a histone deacetylase inhibitor (HDACi) with anti-neoplastic properties, which theoretically reactivates epigenetically silenced genes by increasing global histone acetylation. However, recent studies indicate that a similar number or even more genes are down-regulated than up-regulated by this drug. We treated hepatocarcinoma HepG2 cells with butyrate and characterized the levels of acetylation at DNA-bound histones H3 and H4 by ChIP-chip along the ENCODE regions. In contrast to the global increases of histone acetylation, many genomic regions close to transcription start sites were deacetylated after butyrate exposure. In order to validate these findings, we found that both butyrate and trichostatin A treatment resulted in histone deacetylation at selected regions, while nucleosome loss or changes in histone H3 lysine 4 trimethylation (H3K4me3) did not occur in such locations. Furthermore, similar histone deacetylation events were observed when colon adenocarcinoma HT-29 cells were treated with butyrate. In addition, genes with deacetylated promoters were down-regulated by butyrate, and this was mediated at the transcriptional level by affecting RNA polymerase II (POLR2A) initiation/elongation. Finally, the global increase in acetylated histones was preferentially localized to the nuclear periphery, indicating that it might not be associated to euchromatin. Our results are significant for the evaluation of HDACi as anti-tumourogenic drugs, suggesting that previous models of action might need to be revised, and provides an explanation for the frequently observed repression of many genes during HDACi treatment.

E-mail alvaro.rada{at}genpat.uu.se; fax 46-18-471-4808.

⁵ E-MAIL Claes.Wadelius{at}genpat.uu.se; fax 46-18-471-4808.

[Supplemental material is available online at www.genome.org. The microarray data presented in this work have been submitted to ArrayExpress database, with accession number E-MEXP-693. The processed ChIP-chip data can be visualized at www.genome.ucsc.edu using the Human May 2004 (hg17) Assembly.]

Article is online at http://www.genome.org/cgi/doi/10.1101/gr.5540007

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Y.-C. Lin, J.-H. Lin, C.-W. Chou, Y.-F. Chang, S.-H. Yeh, and C.-C. Chen Statins Increase p21 through Inhibition of Histone Deacetylase Activity and Release of Promoter-Associated HDAC1/2 Cancer Res., April 1, 2008; 68(7): 2375 - 2383. [Abstract] [Full Text] [PDF]